Astrazeneca

 Page 2 

LATEST

Bid for AstraZeneca shows how boards feel swamped by short-term thinking

Here is some excellent advice from an old hand to the directors of AstraZeneca should Pfizer, as expected, get serious about bidding and increase its current £48-a-share offer: don't be swayed by the views of investment bankers chasing success fees; don't judge bid premiums based on a two- to three-year view; and remember you have responsibilities beyond price.

HOT LIST

FEATURED